Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
Axel De Greef, Pierre‐Dominique Ghislain, Laurence de Montjoye, et al.
Advances in Therapy (2023) Vol. 40, Iss. 5, pp. 2509-2514
Open Access | Times Cited: 22

Showing 22 citing articles:

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 953-961
Open Access | Times Cited: 25
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 593-604
Open Access | Times Cited: 8
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Long-term outcomes of upadacitinib in patients with prior dupilumab exposure: a case series
Stamatios Gregoriou, Ioannis‐Alexios Koumprentziotis, Ileana Afroditi Kleidona, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study
Stephan Weidinger, Tobias Schadeck, Felix Jacobs, et al.
Dermatology and Therapy (2025)
Open Access
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management
Giovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 54-54
Open Access
Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study
Francisco Javier Melgosa Ramos, V.A. González-Delgado, José María Sánchez Motilla, et al.
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 4
Closed Access | Times Cited: 8
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
Qingying He, Xin Xie, Qian Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting
Cataldo Patruno, Giuseppe Lauletta, Elena Pezzolo, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 8, pp. 629-634
Closed Access | Times Cited: 3
The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients
Lu Li, Naming Wu, Tingyu Liu, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111193-111193
Closed Access | Times Cited: 5
The Role of Tralokinumab in the Treatment of Atopic Dermatitis and Future Perspectives for Adolescents
Adaora Ewulu, Stuti Prajapati, Steven R. Feldman
Immunotherapy (2023) Vol. 15, Iss. 16, pp. 1341-1349
Closed Access | Times Cited: 4
Skin Barrier Function and Microtopography in Patients with Atopic Dermatitis
Carlota Pretel-Lara, Raquel Sanabria-de la Torre, Salvador Arias‐Santiago, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 19, pp. 5861-5861
Open Access | Times Cited: 1
Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis: A 24-week Retrospective Study
J. Naharro-Rodríguez, Emilio Berna‐Rico, F.J. Pérez-Bootello, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 6, pp. 615-617
Open Access | Times Cited: 1
Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients
Maddalena Napolitano, Silvia Ferrucci, Luciano Foggia, et al.
Clinical Drug Investigation (2023) Vol. 44, Iss. 1, pp. 71-77
Closed Access | Times Cited: 3
[Artículo traducido] Experiencia en práctica clínica real con upadacitinib en adolescentes y adultos con dermatitis atópica refractaria: un estudio retrospectivo de 24 semanas
J. Naharro-Rodríguez, E. Berná-Rico, F.J. Pérez-Bootello, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 6, pp. T615-T617
Open Access
Treatment of atopic dermatitis with upadacitinib: adcare single center experience
Daria Fomina, Olga A. Мukhina, Valeria I Mikhailova, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis
Marielos I. Posada Posada, Maria Beatrice Alora, Xinaida Taligare Vasconcelos Lima
Archives of Dermatological Research (2024) Vol. 316, Iss. 5
Closed Access
Upadacitinib - New Janus Kinase Inhibitor - Literature Review
Michalina Grzelka, Jakub Plizga, Agnieszka Głuszczyk, et al.
Quality in Sport (2024) Vol. 21, pp. 54037-54037
Open Access
Development of a sensitive and simple method for the analysis of upadacitinib in biological samples using two different electrodes
Fatma Budak, Ahmet Çetinkaya, S. Irem Kaya, et al.
Ionics (2024)
Closed Access
Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study
Alexandre Beyrouti, Juliette Deuze, Éric Fontas, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective
Alba Guglielmo, Maria Ludovica Deotto, Luigi Naldi, et al.
Dermatology Reports (2023)
Open Access
Page 1

Scroll to top